Bind Therapeutics Company Profile (NASDAQ:BIND)

About Bind Therapeutics

Bind Therapeutics logoBIND Therapeutics, Inc. is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company's product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS are polymeric nanoparticles that incorporate therapeutic payloads with diverse physical and chemical properties, provide prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. Its drug candidate, BIND-014, which has entered clinical development, is a prostate specific membrane antigen (PSMA)-targeted ACCURIN that contains docetaxel, a clinically validated cancer chemotherapy drug. It designs ACCURINS with specific pharmaceutical properties intended to target tumors at approximately three levels, such as tissue, cellular and molecular.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIND
  • CUSIP:
Key Metrics:
  • Previous Close: $0.78
  • 50 Day Moving Average: $0.52
  • 200 Day Moving Average: $1.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.79
Additional Links:
Companies Related to Bind Therapeutics:

Analyst Ratings

Consensus Ratings for Bind Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $7.44 (853.53% upside)

Analysts' Ratings History for Bind Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016Stifel NicolausReiterated RatingHoldView Rating Details
4/7/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
4/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
4/7/2016Oppenheimer Holdings Inc.DowngradeMarket PerformView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $6.00View Rating Details
12/4/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$20.00 -> $10.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Bind Therapeutics (NASDAQ:BIND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016        
5/9/2016Q116($0.55)($0.61)$3.83 million$1.87 millionViewListenView Earnings Details
3/15/2016Q415($0.49)($0.37)$3.35 million$6.40 millionViewListenView Earnings Details
11/2/2015Q315($0.52)($0.49)$3.14 million$2.10 millionViewN/AView Earnings Details
8/6/2015Q215($0.51)($0.51)$3.88 million$2.50 millionViewListenView Earnings Details
5/7/2015Q115($0.51)($0.44)$2.67 million$4.40 millionViewListenView Earnings Details
3/11/2015Q414($0.40)($0.51)$6.00 million$3.00 millionViewListenView Earnings Details
11/6/2014($0.31)($0.44)ViewN/AView Earnings Details
8/7/2014Q214($0.60)($0.51)$2.20 million$2.46 millionViewN/AView Earnings Details
5/9/2014($0.49)($0.51)ViewN/AView Earnings Details
3/25/2014($0.41)($0.50)ViewN/AView Earnings Details
11/5/2013Q313($0.67)($2.70)$1.66 million$4.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bind Therapeutics (NASDAQ:BIND)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.61)($0.58)($0.60)
Q2 20162($0.48)($0.46)($0.47)
Q3 20162($0.48)($0.46)($0.47)
Q4 20162($0.49)($0.47)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bind Therapeutics (NASDAQ:BIND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bind Therapeutics (NASDAQ:BIND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2013Noubar AfeyanDirectorBuy20,000$15.00$300,000.00View SEC Filing  
9/25/2013Polaris Venture Management Co.Major ShareholderBuy26,000$15.00$390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bind Therapeutics (NASDAQ:BIND)
DateHeadline
globenewswire.com logoDelisting of Securities of BIND Therapeutics, Inc., InterCloud Systems, Inc., Echo Therapeutics, Inc., 1347 Capital ... - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - September 24 at 3:45 PM
openpr.com logoDemand for novel drug delivery systems are driving the Nanotechnology Market to reach US$ 11.9 Bn in 2023 (NASDAQ:BIND)
www.openpr.com - September 23 at 8:55 AM
News IconBIND Therapeutics Stipulation Approved - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 22 at 8:04 AM
4-traders.com logoAgios Pharmaceuticals : Appoints Andrew Hirsch as Chief Financial Officer (NASDAQ:BIND)
www.4-traders.com - September 21 at 8:23 AM
News IconDNIB UNWIND INCORPORATED (OTCMKTS:BINDQ) Shorted Shares Increased 1613.68% After Market Selling - Post News (NASDAQ:BIND)
www.kentuckypostnews.com - September 16 at 3:47 PM
investingnews.com logoHow Do You Define Nanotechnology? - Investing News Network (press release) (registration) (blog) (NASDAQ:BIND)
investingnews.com - September 15 at 8:46 PM
News IconBIND Therapeutics Combined Plan Filed - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 15 at 8:46 PM
finance.yahoo.com logoHercules’ Leading Originations Platform Continues to Finance Some of the Most Promising Innovative and … (NASDAQ:BIND)
finance.yahoo.com - September 15 at 12:44 PM
News IconBIND Therapeutics Combined Plan Filed (NASDAQ:BIND)
bankruptcompanynews.com - September 15 at 12:44 PM
News IconBIND Therapeutics Extension Approved - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 14 at 3:50 PM
News IconProMIS Neurosciences announces positive validation of novel ... - Yahoo Sports (NASDAQ:BIND)
sports.yahoo.com - September 13 at 5:04 PM
News Icon'Leap of faith' in HIF leads to Lasker Award, clinical trials - BioWorld Online (NASDAQ:BIND)
www.bioworld.com - September 13 at 5:04 PM
finance.yahoo.com logoSiamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium - Yahoo Finance (NASDAQ:BIND)
finance.yahoo.com - September 13 at 8:43 AM
globenewswire.com logoBeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - September 12 at 8:38 AM
prnewswire.com logoXencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute ... - PR Newswire (press release) (NASDAQ:BIND)
www.prnewswire.com - September 12 at 8:38 AM
News IconCantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the ... - EconoTimes (NASDAQ:BIND)
www.econotimes.com - September 7 at 3:51 PM
businesswire.com logoProclara Biosciences Announces $47 Million in New Investment to ... - Business Wire (press release) (NASDAQ:BIND)
www.businesswire.com - September 7 at 3:51 PM
News IconNew HIF-2 kidney cancer therapy more effective than current treatment, study shows (NASDAQ:BIND)
www.utsouthwestern.edu - September 6 at 8:40 PM
News IconNew HIF-2 kidney cancer therapy more effective than current treatment, study shows - Science Daily (NASDAQ:BIND)
www.sciencedaily.com - September 5 at 3:45 PM
News IconBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals ... - Madison.com (NASDAQ:BIND)
host.madison.com - September 2 at 3:40 PM
finance.yahoo.com logoLong Acting Growth Hormone Based on Amunix' XTEN(R ... - Yahoo Finance (NASDAQ:BIND)
finance.yahoo.com - September 1 at 12:18 PM
News IconResolve Therapeutics Quantifies Circulating RNA Role in Lupus, Plans CDx for Investigational Therapy - GenomeWeb (NASDAQ:BIND)
www.genomeweb.com - September 1 at 12:18 PM
News IconAwaken Dormant DNA, Epigenetically - Genetic Engineering & Biotechnology News (NASDAQ:BIND)
www.genengnews.com - September 1 at 12:18 PM
finance.yahoo.com logoWarp Drive Bio Awarded Patent Covering Proprietary Method for ... - Yahoo Finance (NASDAQ:BIND)
finance.yahoo.com - August 31 at 3:49 PM
globenewswire.com logoMerus to Participate in Upcoming Investor Conferences Nasdaq ... - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - August 31 at 3:49 PM
News IconSpherical RNA therapy shows promise against psoriasis in first human trial - Science Magazine (NASDAQ:BIND)
www.sciencemag.org - August 31 at 3:49 PM
seekingalpha.com logoShareholders in BIND Therapeutics hit the sell button after record date for future payouts; shares down 66% - Seeking Alpha (NASDAQ:BIND)
seekingalpha.com - August 31 at 3:49 PM
News IconPfizer Inc. (NYSE:PFE) Buys BIND’s Assets (NASDAQ:BIND)
learnbonds.com - August 25 at 3:54 PM
News IconWall Street Ratings and Update on BIND Therapeutics, Inc ... - Post News (NASDAQ:BIND)
www.kentuckypostnews.com - August 22 at 3:53 PM
4-traders.com logoDNIB Unwind : Bind Therapeutics reports 2Q loss (NASDAQ:BIND)
www.4-traders.com - August 16 at 12:34 PM
News IconFormer BIND Therapeutics CEO Joins Agios as New CFO (NASDAQ:BIND)
www.biospace.com - August 16 at 12:34 PM
sg.finance.yahoo.com logoBind Therapeutics reports 2Q loss (NASDAQ:BIND)
sg.finance.yahoo.com - August 16 at 12:34 PM
News IconBIND Therapeutics Inc (OTCMKTS:BINDQ): What Can Shareholder's Expect? - Insider Financial (NASDAQ:BIND)
www.insiderfinancial.com - August 3 at 3:53 PM
News IconIntraday Active Biotech Stocks News: Nektar Therapeutics (NASDAQ:NKTR), BIND Therapeutics, Inc. (NASDAQ:BIND) - The Voice Registrar (NASDAQ:BIND)
voiceregistrar.com - August 3 at 12:30 PM
prnewswire.com logoBiotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma - PR Newswire (press release) (NASDAQ:BIND)
www.prnewswire.com - August 3 at 12:30 PM
biz.yahoo.com logoDNIB UNWIND, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:BIND)
biz.yahoo.com - August 2 at 9:30 PM
biz.yahoo.com logoBIND THERAPEUTICS, INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Amendments to Articles (NASDAQ:BIND)
biz.yahoo.com - August 2 at 8:39 AM
News IconHC Stocks Movements: BIND Therapeutics Inc (NASDAQ:BIND) Amedica Corporation (NASDAQ:AMDA) - share market updates (press release) (NASDAQ:BIND)
sharemarketupdates.com - August 1 at 8:46 AM
fortune.com logoAnalyst Ratings Worth Mentioning Today: Globalstar, Inc. (NYSEMKT:GSAT), BIND Therapeutics Inc (NASDAQ:BIND) - Review Fortune (NASDAQ:BIND)
reviewfortune.com - August 1 at 8:46 AM
streetupdates.com logoStock's Ratings to Focus: Skyline Medical Inc. (NASDAQ:SKLN) , BIND Therapeutics, Inc. (NASDAQ:BIND) - Street Updates (NASDAQ:BIND)
www.streetupdates.com - August 1 at 8:46 AM
streetupdates.com logoTraders Actions to Focus: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , BIND Therapeutics, Inc. (NASDAQ:BIND) - Street Updates (NASDAQ:BIND)
www.streetupdates.com - July 29 at 7:40 AM
fortune.com logoNotable Brokerage Recommendations: Cliffs Natural Resources Inc (NYSE:CLF), BIND Therapeutics Inc (NASDAQ ... - Review Fortune (NASDAQ:BIND)
reviewfortune.com - July 28 at 4:55 PM
News IconRecommendation Trends of the Stock: BIND Therapeutics, Inc. (NASDAQ:BIND) - News Oracle (NASDAQ:BIND)
www.newsoracle.com - July 28 at 4:55 PM
biz.yahoo.com logoBIND THERAPEUTICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or Failure (NASDAQ:BIND)
biz.yahoo.com - July 28 at 4:07 PM
4-traders.com logoBIND Therapeutics : Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets (NASDAQ:BIND)
www.4-traders.com - July 28 at 12:36 PM
wsj.com logoPfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics (NASDAQ:BIND)
www.wsj.com - July 27 at 9:36 PM
law360.com logoBind Therapeutics Wins OK Of $40M Ch. 11 Sale to Pfizer (NASDAQ:BIND)
www.law360.com - July 27 at 9:36 PM
wsj.com logo[$$] Pfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics (NASDAQ:BIND)
www.wsj.com - July 27 at 12:55 PM
News IconSirius XM Holdings Inc. (NASDAQ:SIRI) & BIND Therapeutics (NASDAQ:BIND) Active Stock's Momentum - Money News (press release) (NASDAQ:BIND)
www.newsismoney.com - July 27 at 12:20 PM
reuters.com logoBRIEF-Bind Therapeutics determines Pfizer's $40 mln bid highest - Reuters (NASDAQ:BIND)
www.reuters.com - July 27 at 12:20 PM

Social

Bind Therapeutics (NASDAQ:BIND) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff